Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
385 studies found for:    "primary myelofibrosis"
Show Display Options
RSS Create an RSS feed from your search for:
"primary myelofibrosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Peginterferon alfa-2a
2 Suspended Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Condition: Primary Myelofibrosis
Interventions: Drug: Imetelstat 9.4 milligram/kilogram (mg/kg);   Drug: Imetelstat 4.7 mg/kg
3 Terminated
Has Results
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib
4 Completed Thalidomide in Treating Patients With Myelofibrosis
Condition: Primary Myelofibrosis
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
5 Withdrawn A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
Condition: Primary Myelofibrosis
Intervention: Biological: Pacritinib
6 Completed Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: APLIDIN (plitidepsin)
7 Active, not recruiting
Has Results
Decitabine in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis
8 Recruiting P1101 in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Other: Laboratory Biomarker Analysis;   Biological: PEG-Proline-Interferon Alfa-2b;   Other: Quality-of-Life Assessment
9 Recruiting Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Condition: Myelofibrosis
Interventions: Drug: Ruxolotinib;   Drug: peg-IFN alpha -2a
10 Active, not recruiting
Has Results
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence
Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide 0.5 mg;   Drug: Placebo
11 Recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
12 Completed A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: SAR302503 (TG101348)
13 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
14 Recruiting Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Condition: Myelofibrosis
Intervention:
15 Active, not recruiting Lenalidomide for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Lenalidomide;   Drug: Prednisone
16 Completed
Has Results
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Condition: Primary Myelofibrosis (MF)
Intervention: Drug: Ruxolitinib
17 Recruiting JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: Ruxolotinib
18 Recruiting Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Condition: Myelofibrosis
Interventions: Drug: Panobinostat;   Drug: Ruxolitinib
19 Not yet recruiting Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Condition: Myelofibrosis
Intervention: Other: Hematopoietic Stem Cell Transplant
20 Recruiting JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.